3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 1/2
1
Phase 1
1
Status
Unknown
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Adenomatous Polyposis Coli
2
Urinary Bladder Neoplasms
1
Precancerous Conditions
1
Glioma
1
Colorectal Neoplasms
1
Colonic Polyps
1
Carcinoma, Basal Cell
1
Brain Neoplasms
1
Astrocytoma
1
Interventions
Temozolomide
16
Radiotherapy
11
Lomustine
8
Carmustine
6
Vincristine
5
Procarbazine
5
Etoposide
3
Corticotropin-Releasing Hormone
3
Carboplatin
3
vorasidenib
2
Thiotepa
2
Radiotherapy, Intensity-Modulated
2
Peripheral Blood Stem Cell Transplantation
2
Methotrexate
2
Isotretinoin
2
Everolimus
2
Dihematoporphyrin Ether
2
Cisplatin
2
Chemotherapy, Adjuvant
2
etoposide phosphate
1
carmustine, poliferprosan 20 drug combination
1
Valproic Acid
1
Tranexamic Acid
1
Trabedersen
1
Thioguanine
1
Surgical Procedures, Operative
1
Semustine
1
Radiotherapy, Conformal
1
Radiosurgery
1
Prednisone
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Astrocytoma
×
Eflornithine
×
Clear all
NCT02796261
2022-01-21
STELLAR
Orbus Therapeutics, Inc.
Phase 3
Unknown
343 enrolled